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AshkenaziThe high prevalence of genetic diseases resulting from gross deletions has highlighted a need for a quick, simple,
and reliable method of genotyping these mutations. Here, we developed a novel strategy for applying TaqMan
allelic discrimination to accurately genotype 3 different large deletions in a high-throughput manner. Allelic
discrimination has previously been used to genotype frame shift and point mutations, and small insertions or
deletions six base pairs in length, but not large deletions. The assays designed here recognize a 2502 base pair
deletion in the Nebulin (NEB) gene that results in Nemaline Myopathy, a 308,769 base pair deletion in the
Gap Junction Protein, beta 6 (GJB6) gene that causes Hearing Loss, and a 6433 base pair deletion in theMucolipin
1 (MCOLN1) gene responsible for causing Mucolipidosis IV Disease. This methodology may also be successfully
applied to high throughput genotyping of other large deletions.
© 2012 Elsevier Inc. All rights reserved.1. Introduction
Due to the high demand for quick and accurate diagnosis of numer-
ous genetic diseases, many advances have been made in terms of
detecting mutations and determining genotypes [1]. One of the most
efﬁcient ways to analyze genotypes is through the TaqMan allelic
discrimination, which has frequently been used to characterize single
nucleotide polymorphisms (SNPs). There are many diseases that result
from large deletions, however, that until nowhave only been detectable
by copy number analysis, multiplex ligation-dependent probe ampliﬁ-
cation [2], or direct sequencing [3], but these methods can be time
consuming, expensive, and difﬁcult to interpret and apply in studies
requiring high throughput. An alternative approach would be to use
TaqMan allelic discrimination technology, similar to how it has been
applied to genotype SNPs, to determine the genotypes of gross deletion
mutations.
Although TaqMan technology has been applied before to an inser-
tion/deletion polymorphism of 276 base pairs in length [4], there are
genetic diseases that result from much larger deletions such as Nema-
line Myopathy or Mucolipidosis IV. In the present study, publically
available primer and probe design software was used to design TaqMan
assays that operate under universal conditions and could successfully
genotype three different gross deletions ranging in size from 2.5 to
309 kilobases.son Ave, Suite 100 Morristown,
rights reserved.2. Results
The ﬁrst mutation analyzed was the 2,502 base pair deletion in the
NEB gene (Fig. 1A). During the initial analysis, (when the two assays
were individually used) ﬁve different gDNA samples and a no template
control were evaluated. As shown in Fig. 1B, four of the ﬁve gDNA sam-
ples ampliﬁedwith theNEBwild type assay (NEBwt). Similarly, the NEB
deletion assay (NEBdel) showed that two gDNA samples had ampliﬁed
and three had not. The combination of the two independent results
could be used to distinguish between homozygous wild type, heterozy-
gous, and homozygous mutant genotypes. It became apparent that one
gDNA sample had ampliﬁed in both plots, while the remaining four
gDNA samples had only ampliﬁed in one of the plots. These results
were consistent with previous characterization of the genotypes of
each sample. The sample that had ampliﬁed in both plots was the het-
erozygous carrier sample, while the wild type samples only ampliﬁed
when the wild type assay was used and the homozygous affected
sample only ampliﬁed when the deletion assay was used. Due to the
success of the individual assays, the two assays were combined and
run against the same gDNA samples and no template control. After
combining the assays, the allelic discrimination plot showed three
distinct clusters representing the three different genotypes. These
three clusters were representative of the samples, with the three wild
type samples gathered together and clearly separated from the hetero-
zygous carrier sample, which was in turn separated from the homozy-
gous affected sample. The accuracy of the combined assay prediction,
based on the previous knowledge of the samples and the previous
uses of the assays individually, was 100%.
The next mutation analyzed was the 308,769 base pair deletion in
the GJB6 gene (Fig. 2A). During the initial analysis, four gDNA samples
Fig. 1. NEB Deletion. Fig. 1A: Strategy for designing the assay. Nucleotide (nt) positions from 152504773 to 152502272 are shown. The genome build is GRCh37.3 (hg19). Primers
are indicated by italics and arrows. The probe is indicated by bold print and is underlined. Fig. 1B: Allelic discrimination plots for wild type, deletion, and combination assays. For the
wild type assay, the heterozygous carrier and wild type samples ampliﬁed. For the deletion assay, the heterozygous carrier and homozygous affected samples ampliﬁed. When the
wild type and deletion assays were combined in one reaction, the various genotypes were separated on one plot into individual clusters. The wild type sequence was used as the VIC
probe and the deletion sequence was used as the FAM probe. NTC=No template control.
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GJB6 wild type assay (GJB6wt) revealed four ampliﬁed gDNA samples,
while the GJB6 deletion assay (GJB6del) had only one ampliﬁed sample.
Inspection conﬁrmed that the heterozygous carrier sample was the
sample that had ampliﬁed for both assays, and that the wild type
samples had only ampliﬁed when exposed to the wild type assay. The
assays were then combined and tested on the original samples, as
well as two additional heterozygous carrier samples. Once again, the
allelic discrimination plot showed a distinct separation between the
two different genotypes, and had an accuracy of 100%.
Finally, the 6.4 kb deletion in the MCOLN1 gene was analyzed
(Fig. 3A). This mutation was particularly hard to design a deletion
assay for because it had many short tandem repeats in its sequence.
Both a wild type and a deletion assay were designed and individuallyFig. 2. GJB6 Deletion. Fig. 2A: Strategy for designing the assay. Nt. Positions 19695144 to 20003
arrows. The probe is indicated by bold print and is underlined. Fig. 2B: Allelic discriminationplot
carrier and wild type samples ampliﬁed. For the deletion assay, the heterozygous carrier ampl
genotypes were separated on one plot into individual clusters. The wild type sequence was ustested on three wild type, two heterozygous carriers, and a no template
control sample. The success of the individual assays (as shown in
Fig. 3B) led the two assays to be combined and tested on the same
samples. The combined assayswere again able to genotype the samples
with an accuracy of 100%.
In order to further validate the accuracy of the assays, a blind study
was performed for theNEB deletion (Fig. 4). Twenty newgDNA samples
were extracted from new blood samples ofwhich the genotypewas not
provided. After running the wild type and deletion assays for the NEB
deletion in combination, two distinct clusters were observed, with ten
of the blind samples falling into the heterozygous carrier cluster and
ten falling into the homozygous wild type cluster. Controls for all
three possible genotypes, along with a no template control, were also
included in the study. All of the samples were run in duplicate in910 are shown. The genome build is GRCh37.3 (hg19). Primers are indicated by italics and
s forwild type, deletion, and combination assays. For thewild type assay, theheterozygous
iﬁed. When the wild type and deletion assays were combined in one reaction, the various
ed as the VIC probe and the deletion sequence was used as the FAM probe.
Fig. 3.MCOLN1Deletion. Fig. 3A: Strategy for designing the assay. Nt. positions 7586614 to 7593104 are shown. The genome build is GRCh37.3 (hg19). Primers are indicated by italics and
arrows. The probe is indicated by bold print and is underlined. Fig. 3B: Allelic discriminationplots forwild type, deletion, and combination assays. For thewild type assay, theheterozygous
carrier andwild type samples ampliﬁed. For the deletion assay, the heterozygous carrier ampliﬁed.When thewild type and deletion assayswere combined in one reaction, the genotypes
were separated on one plot into individual clusters. The wild type sequence was used as the VIC probe and the deletion sequence was used as the FAM probe.
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representing two different samples did not cluster, but remained in
between the homozygous wild type and heterozygous carrier clusters,
making their call “Undetermined.” Since both samples also had a repli-
cate that did cluster, however, genotypes were still able to be assigned
to these samples. The original genotypes for the blind samples were
then obtained, revealing that all twenty samples had been correctly
genotyped, making this method 100% accurate.
Finally, in order to ensure that this procedure was applicable to
high-throughput processes, a carrier frequency study was also done
for the NEB deletion (Fig. 5). One thousand one hundred and forty-six
gDNA samples obtained from individuals of Ashkenazi Jewish heritage
were plated in duplicate and genotyped using real time PCR and
TaqMan allelic discrimination. The homozygous wild type and hetero-
zygous carrier samples clearly separated from each other, allowing the
samples to be genotyped. Fifteen samples were identiﬁed as being het-
erozygous carriers, revealing a carrier frequency of 1.3% (15/1146). This
is comparable to the published carrier frequency of 0.92% (1/108) [5].Fig. 4. Blind Study for NEB deletion. Allelic discrimination plot showing the genotypes for twen
are in black. All of the blind samples were plated in duplicate. Two of the samples had individu
two samples had a replicate that did cluster, however, a genotype was still assigned for the sam
carriers.These results therefore indicate that not only can TaqMan SNP
assays be used to correctly genotype gross deletion mutations, but
that combining the deletion and wild type assays can allow for a single,
accurate, genotyping reaction to take place. Furthermore, the carrier
frequency study also proves that these assays are amenable to high-
throughput procedures.
3. Discussion
When originally genotyping the above deletions, two TaqMan
assays were designed with one targeting the wild type sequence and
the other the deletion sequence. The two assays were individually run
as two separate reactions, and afterwards the two ampliﬁcation plots
were compared to determine the genotypes of the samples. For these
assays, the gDNA of a heterozygous carrier would amplify for both
assays, but the wild type gDNA would only amplify in the wild type
sequence assay and homozygous affected gDNA would only amplify in
the deletion sequence assay. This method, while accurate and morety blind gDNA samples. The blind samples are depicted in gray, while the control samples
al replicates that did not cluster, which were therefore called “Undetermined.” Since these
ples. Of the twenty samples, ten were homozygous wild type and ten were heterozygous
Fig. 5. Carrier Frequency Study for NEB deletion. Allelic discrimination plot showing the carrier frequency for the NEB deletion. One thousand one hundred and forty-six gDNA
samples obtained from individuals of Ashkenazi Jewish heritage were plated in duplicate and genotyped. The experimental samples are depicted in gray, while the control samples
are in black. Fifteen samples were identiﬁed as being heterozygous carriers, revealing a carrier frequency of 1.3% (15/1146).
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could be because it required using twice the amount of gDNA as a
normal SNP assay would require, and it took more preparation time.
By combining the wild type and deletion assays for use in one reaction,
less gDNA is needed and the data can appear on one ampliﬁcation plot,
making the results easier to interpret. Importantly, the combined wild
type and deletion assays act in exactly the same manner as normal
SNP genotyping assays.
The beneﬁt of using TaqMan assays to genotype gross deletions
extends to numerous endeavors, with the primary advantage being
that the TaqMan assays are more efﬁcient in genotyping. Alternative
methods for characterizing deletion mutations, such as multiplex
ligation-dependent probe ampliﬁcation and DNA sequencing, require
the use of electrophoresis for analysis, which is not only time consum-
ing, but can also be difﬁcult to interpret. Furthermore, TaqMan assays
such as these can be applied to carrier frequency studies where a
gross deletion is the mutation causing the genetic disease. Due to the
ability of TaqMan assays to be applied to high throughput screening,
these assays can replace the need for copy number analysis for certain
mutations, and instead allow for a qualitative approach.
The incorporation of TaqMan deletion assays, such as the ones
featured here, into genetic screens will lead to more proﬁcient and
accurate genotype diagnoses for potential carriers. For instance, the
three deletion mutations highlighted in this paper are very prevalent
in the Ashkenazi Jewish population and therefore screened for often.
Haplotype testing using microsatellite markers has indicated a founder
effect for both the NEB and the GJB6 deletion in the Ashkenazi Jewish
population with a carrier frequency of 1 in 108 [5] for the ﬁrst and a
homozygous affected rate of 0.5% for Israeli Ashkenazi Jews for the latter
[6]. Similarly, by using a TaqMan platform to generate cycle threshold
(Ct) and relative ﬂuorescence unit values, an allele mutation rate of
0.24% was found in the Ashkenazi Jewish population for the MCOLN1
deletion [7]. The high prevalence of these speciﬁc mutations necessi-
tates not only the development of the above TaqMan deletion assays,
but also the knowledge that the productions of such assays are feasible
in general.4. Materials and methods
4.1. Population
The gDNA used in this study was obtained from individuals of
Ashkenazi Jewish ancestry. The gDNA was extracted from blood, and
the concentrations were obtained via Nanodrop (Thermo FisherScientiﬁc Inc., Wilmington, DE, USA). The gDNA was then normalized
to 5 ng/μL.
4.2. Experimental design
The goal of this research was to determine if TaqMan SNP assays
(Applied Biosystems Inc. [AB], Carlsbad, CA, USA) could be used to
successfully genotype large deletions by discriminating homozygous
wild type, heterozygous carrier, and homozygous affected genotypes.
Each pair of assays was tested on either known heterozygous carrier
gDNA and/or homozygous affected gDNA that was speciﬁc for the
disease the assay was designed to detect. The number of samples for
each assay varied based on the availability of the gDNA. In all of the
tests, three wild type gDNA controls, as well as a no template control,
were always included. The gDNA was plated in duplicate in 384 well
plates along with TaqMan Master Mix (AB) and the pairs of assays,
resulting in a ﬁnal volume of 5 μL. 10 ng of template DNA was used
per reaction. The plates were centrifuged for 1 minute, sealed, and
then run in duplex real time PCR reactions using FAM and VIC as the
detector probes. After the real time PCRwas ﬁnished, allelic discrimina-
tion analysis was performed using SDS 2.3 software (AB). This allowed
the assay performance to be evaluated.
For the blind study, twenty gDNA samples were extracted from
twenty blood samples and then normalized to 5 ng/μL. The genotypes
for these samples were not known throughout the blind study. In addi-
tion to the twenty samples of unknown genotype, three wild type sam-
ples, one heterozygous carrier, and one homozygous affected gDNA
sample, as well as a no template control, were run as controls. The
gDNA was plated in duplicate in 384 well plates along with TaqMan
Master Mix (AB) and the pair of assays, resulting in a ﬁnal volume of
5 μL. 10 ng of template DNA was used per reaction. The plates were
centrifuged for 1 minute, sealed, and then run in duplex real time PCR
reactions using FAM and VIC as the detector probes. After the real
time PCR was ﬁnished, allelic discrimination analysis was performed
using SDS 2.3 software (AB) to genotype the samples. Genotypes were
assigned to the twenty blind samples based on their clustering. The
samples’ original genotypes were then revealed for comparison. All of
the samples were correctly assigned the right genotype.
For the carrier frequency study, 1 μL gDNAwas plated in duplicate in
384 well plates containing 3 μL of water. The gDNAwas not normalized
prior to plating. The plates were then dried and refrigerated until need-
ed. Thewild type and deletion assays were then added at equal volume,
along with TaqMan Master Mix (AB) and water to bring the ﬁnal
volume to 5 μL. The plates were centrifuged for 1 minute, sealed, and
then run in duplex real time PCR reactions using FAM and VIC as the
Table 1
Primer and probe sequences for the wild type and deletion assays.
Assay name Forward primer sequence Reverse primer sequence VIC probe sequence FAM probe sequence
NEBwt AAAGTGCCAGACACACACATCT TGTCTCATTGATTCCTTAAACTTGTCCAT CTTTGAGGTATGCAGCATG CCTTTGAGGTATTCAGCATG
NEBdel GCTTCTCTGGGTTATATGCACCAT ATTCTCCTGCGTGGGTTTTGTAT ACATCTCATGCTGTAGTGAG TCTCATGCTGCAGTGAG
GJB6wt ACGTACACCAGCAGCATCTTTT GGGTCAATCCCACATTTCAACAC ACATAAAGGCTGCTTCAA ATACATAAAGGCTACTTCAA
GJB6del CCACCTTCCGTCTCTATGAATTTGA GGGTCAATCCCACATTTCAACAC TGTAAAGGAAGTAGAACACA TGTAAAGGAAGTAAAACACA
MCOLN1wt GGGCTGCCAAGGTTTACTCT CTGGGTCTCCAGGCTGATG TGTGCTTTGTTGTCAAAC TGTGCTTTGTTATCAAAC
MCOLN1del GTGCAGTGGTGTGATCATAGCT GGATCCGCCCACTGTGT TCCTGGGCTTAACAAA CTGGGCTCAACAAA
131A. Fedick et al. / Genomics 99 (2012) 127–131detector probes. After the real time PCRwas ﬁnished, allelic discrimina-
tion analysis was performed using SDS 2.3 software (AB) and results
were compiled using TaqMan Genotyper Software (AB).4.3. Assay design
As indicated in Table 1, two assays each were originally required for
the analysis of the three deletion mutations. A pair of assays was
designed for a 2502 base pair deletion [8] that occurs in the NEB gene
and results inNemalineMyopathy. Another pair of assayswas produced
for a 308,769 base pair deletion [9] in theGJB6 gene that results in Hear-
ing Loss [10]. Finally, two assays were designed to detect a 6433 base
pair deletion [11] that occurs in theMCOLN1 gene and results in Muco-
lipidosis IV Disease [12]. The assays were designed by using NCBI to
search for the full sequence of the gene (FASTA). Once the location of
the breakpoint was found, roughly two hundred base pairs upstream
and downstream of the deletion breakpoint were selected and put
into Repeat Masker to mask for the repeats (Institute for Systems
Biology, Seattle, WA, USA). The original selected sequence was then
put into the NCBI Blast site (SNP Flanks) so that SNPs could be masked.
The primers for the wild type assays were designed by taking either
the ﬁrst nucleotide downstream of the ﬁrst breakpoint or the ﬁrst nu-
cleotide upstream of the second breakpoint, and giving this nucleotide
a false minor allele (which could be any of the remaining three options
for a DNAbase). Thiswas done in order tomake the assay a SNP assay so
that allelic discrimination could be performed. The primers for the
deletion assays were designed by selecting the nucleotide one basepair
upstream of the ﬁrst breakpoint or the nucleotide one basepair down-
stream from the second breakpoint as the minor allele and giving it a
false major allele. Notably, since one allele was artiﬁcial in both of the
assays, the wild type assay only utilized the VIC probe and the deletion
assay only utilized the FAM probe. The assays were then made in File
Builder software (AB).
After the initial success of using the two assays individually to
correctly genotype the large deletions, the assays were combined. Thiscombination utilized both the FAM and VIC probes to genotype the
large deletions in one reaction
4.4. Ethics
All research material was obtained with patient consent and under
IRB approval.
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